Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stock Attack -- A Complete Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Lane who wrote (21174)	5/20/1999 2:22:00 PM
From: jef saunders	Respond to of 42787

DMX on toronto exchange - announces partnership with JNJ. this is the one i've been telling you about, and i've been buying this for a couple of years at $1-$3, stock is now halted. here's part of the news, the whole thing is at exchange2000.com the investor relation's guy said earlier this month it would be happening. news before halt Dimethaid and McNeil Consumer Healthcare agree to exclusive negotiations for U.S. distribution of PENNSAID(R) TORONTO, May 20 /CNW/ - Dimethaid Research Inc. (TSE: DMX) today announced that its wholly owned subsidiary, Dimethaid International Inc. has entered into a standstill agreement with McNeil Consumer Healthcare, a wholly owned subsidiary of Johnson & Johnson (NYSE: JNJ), for the US distribution rights to Dimethaid's PENNSAID(R) Lotion, for which an undisclosed sum was received. The parties have agreed to negotiate exclusively with each other with the intention of concluding a comprehensive distribution agreement. The agreement will include terms under which McNeil Consumer Healthcare will purchase PENNSAID(R) Lotion exclusively from Dimethaid International under a long term arrangement.